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Abstract 
Background: To determine the role of Tiotropium 
as step up therapy for patients with uncontrolled 
asthma.  
Methods: In this case control study 130 patients, 
with diagnosis of bronchial asthma for at least 01 
year and  presently on step 4 treatment and still 
symptomatic, were included . Sixty five patients 
were randomly assigned to receive Tiotropium 
bromide dried inhaler added to their conventional 
step 4 treatment, whereas 65 patients were given 
placebo. Patients were asked about symptomatic 
improvement, using mini AQLQ. Peak Expiratory 
Flow Rate (PEFR)  was checked eight weeks after 
wards to document response to therapy.     
Results: Mean age and duration of diagnosis of 
asthma was 38 years and 5.1 years, respectively in 
cases. Mean PEFR at admission among cases was 210 
l/min (± 58.35) while it was 203 l/min (± 57.32) among 
controls. Frequency of nocturnal awakening were 
2.98 days/ week among cases and 2.88 days/ week 
among controls. At week 8, frequency of nocturnal 
symptoms was found to be 1.6 days/week among 
patients on Tiotropium while it was 2.13 days /week 
among controls. Mean PEF was 387 l/min  among 
Tiotropium group as compared to 305 l/min. There 
was statistically significant improvement in 
symptoms and PEFR of patients on Tiotropium as 
compared to controls. (p value 0.004). The differences 
remained statistically significant after adjusting for 
age and gender.  
Conclusion: Tiotropium daily as maintenance 
treatment through dried inhaler in addition to at 
least high-dose inhaled corticosteroids combined 
with long acting B2 agonists offers significant 
potential to improve airway patency in patients with 
severe persistent asthma who are still symptomatic 
and obstructed on maximal therapy. 
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Introduction 
     Asthma is an inflammatory disorder of the airways 
characterized by variable airflow obstruction and 
airway hyper responsiveness to a variety of stimuli. 
The goal of asthma management is control of its 
symptoms but it is a well documented fact that many 
patients do not achieve this target even after 
maximum doses of inhaled corticosteroids (ICS) and 
long acting B2 agonists (LABA).1,2 If still patients 
remain symptomatic then a second bronchodilator 
with different mechanism of action can be tried like 
Tiotropium bromide which is widely used for 
treatment of COPD.3,4 Tiotropium slowly disassociates 
from muscarinic receptors and hence has got long 
duration of action. By virtue of slow disassociation 
from receptors it has also got slower as well as smaller 
action as compared to short acting bronchodilators 
(SABA) and usually not used in acute Asthma.5,6  In 
contrast although ipratropium is not usually employed 
as a first-line bronchodilator to treat chronic asthma, it 
has been used extensively in emergency departments 
as adjunctive therapy with beta agonists for the 
emergency treatment of acute asthma exacerbations 
and it results in modest improvement in morning peak 
expiratory flow (PEF)7. Whereas Tiotropium is a newer 
long-acting anti cholinergic medication and a few 
clinical trials have been performed to study the use of 
Tiotropium for management of uncontrolled asthma. 
Preliminary evidence suggests that adding 
Tiotropium to medium dose inhaled glucocorticoid 
may be effective treatment in improving uncontrolled 
asthma. Although long term use of anti cholinergic 
drugs for Asthma is not commented  in Global 
initiative for Asthma (GINA) guidelines but  many 
studies showed beneficial role of Tiotropium when 
used as maintenance long term therapy. 2,8,9,10,11    
Recently in Peter et al study it has been proven that in 
mild to moderate asthma uncontrolled with only low 
dose ICS  the addition of Tiotropium to ICS yielded 
much superior improvement in morning PEF as well 
as symptoms and asthma control days as compared to 
doubling the dose of ICS beclomethasone.12 It is also 
noted that Tiotropium was not found inferior to 
Salmeterol. However role of Tiotropium in severe 
uncontrolled asthma is still unexplored extensively.13  
The present study can be taken as one of the pioneer 
work on this topic. 
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Patients and Methods  
       This case control study was carried out in 
department of Pulmonology, Military Hospital 
Rawalpindi, from August 2011 to December 2012. A 
total of 130 patients of uncontrolled bronchial asthma 
on step 4 treatment by consecutive sampling, admitted 
to medical wards with worsening of their symptoms, 
were enrolled. Diagnosis of asthma was based on 
compatible history and physical examination 
supported by spirometry demonstrating airflow 
obstruction with significant reversibility (documenting 
more than 12% change in FVC and 200 ml in FEV1 
post bronchodilator) and there is no alternative 
explanation for the symptoms and airflow obstruction 
(eg, smoking, bronchiectasis,). Inclusion criteria 
included age 40-75 years of age, atleast 01 year history 
of asthma, both male and female gender, non -
smokers, no antibiotic treatment in past 02 weeks. 
Patients with COPD, previous history of tuberculosis, 
resting heart rate more than 100 beats per minute, 
glaucoma, prostatic enlargement, hypersensitivity to 
anti cholinergic, and those with underlying 
malignancy were excluded from study. Prior to 
enrollment, each patients detailed history, clinical 
examination, pulse oximetry, lung function tests were 
reviewed. All the participants were given step 4 
conventional  treatment with ICS , LABA , 
methylxanthines and leukotrienes receptor antagonist 
.Out of 130 patients , 65 patients were randomly 
selected to be given Tiotropium 18 ug daily, while 65 
patients were given placebo. The primary outcome 
was improvement in symptoms as document by mini 
AQLQ (asthma quality of life questionnaire). 
Secondary outcomes were improvement in PEFR at 
eight weeks. Patients were reviewed in clinic eight 
weeks later and asked about symptoms improvement 
to evaluate primary outcome. They were also asked 
about number of nocturnal and day time symptoms, 
hospital visits and compliance to therapy.  Both the 
groups were compared using intention to treat 
analysis. Base line demographic data of two groups 
was compared using student t test for continuous 
variables and ×² test for categorical data. p value of 
less than 0.05 was considered statistically significant. 
 
Results 
       Mean age of cases was 38 years (± 8.96) while that 
of controls was 37.8 yeas (± 8.54). Mean duration of 
diagnosis of asthma was 5.1 years (±2.85) among cases 
and 5.23 years (± 2.75) among controls (Table 1). Mean 
PEFR at admission among cases was 210 l/min (± 
58.35) while it was 203 l/min (± 57.32) among controls 
.  
Table 1: Baseline characteristics of study group 
Demographic 
Characteristic 
Cases Controls p value 
No of patients(n) 65 65  
Age , mean (SD) 38 (± 8.96) 37.8 (± 8.54) 0.29 
Duration of 
asthma(yrs),mean 
(SD) 
5.1 (±2.85) 5.23  (± 2.75) 0.87 
Age of onset of 
asthma (yrs), mean 
(SD) 
23(±4.71) 24.2(± 4.62) 0.41 
Mini AQLQ, mean 
(SD) 
4.6 (±1.2) 4.4 (±1.5) 0.82 
PEFR l/min, mean 
(SD) 
210( 58.35) 203(±57.32) 0.72 
 
Table 2: Response of patients to treatment with 
Tiotropium bromide 
Demographic 
characteristic 
Cases Control p value 
Mini AQLQ  mean 
(SD) 
3.6 (±.98) 4.62 (±.87) 0.002 
Nocturnal 
awakenings 
(nights/wk) mean 
(SD) 
.92 (± .76) 1.8(± .63) 0.03 
Day time 
symptoms (no of 
episodes/wk) 
mean (SD) 
3.27 (± 1.5) 6.23 (± 1.78) 0.04 
PEFR l/min   mean 
(SD) 
365 (±47.6) 304 (± 41.2) 0.032 
Frequency of nocturnal awakening were 2.98 days/ 
week (± 1.78) among cases and 2.88 days/ week ( ± 
1.82) among controls. At week 8, the study participants 
were reassessed for symptoms improvement and PEF 
recording. Frequency of nocturnal symptoms was 
found to be 1.6 days/week (± 1.13) among patients on 
Tiotropium while it was 2.13 days /week (± 1.8) 
among controls. Mean PEF was 387 l/min (± 65) 
among Tiotropium group as compared to 305 l/min (± 
54) (Table 2). There was statistically significant 
improvement in symptoms and PEFR of patients on 
Tiotropium as compared to controls. (p value 0.004). 
The differences remained statistically significant after 
adjusting for age and gender.  
 
Discussion 
    Although most patients of asthma are usually 
controlled with step 4 and 5 treatments but some still 
remain uncontrolled. These patients develop frequent 
exacerbations, drain health resources with progressive 
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decline in patient’s health. This study was designed to 
address this subset of patients and demonstrated 
significant improvement in both symptoms as well as 
pulmonary function in patients treated with 
Tiotropium. Both dried and mist inhalers of 
Tiotropium are used for chronic obstructive air way 
disease but now it has been shown that mist inhaler 
increases cardiovascular mortality in patients of 
COPD14. This study documents a clear superiority of 
Tiotropium compared with controls in asthmatic 
patients whose symptoms are not controlled with at 
least ICS plus LABA treatment in terms of primary 
and secondary spirometry end points and 
symptomatology. Our results are comparable with 
Peter et al study in which milder asthma subjects on 
low dose ICS were selected and here addition of 
Tiotropium produced the similar results.12  It also 
support the results of Michael G et al study however in 
this study selected patients were between 18 to 75 
years of age  and all patients were using high-dose ICS 
>800 mg of budesonide or equivalent and a LABA and 
then they were given Tiotropium for eight weeks as 
compared to our study where we only administered 
Tiotropium for two weeks.13  Similarly effect of 
Tiotropium was comparable with that of COPD 
patients who were given this without LABA in 
Casaburi R et al as well as Tashkin DP et al studies.15,16 
In animal models of allergic asthma it has been shown 
that Tiotropium also has got anti inflammatory effects 
but in our study we only focused towards spirometry 
and symptomatic outcomes and eosinophillia as well 
as other markers of inflammation were not 
evaluated.17  Role of Tiotropium in combination with 
ICS and LABA as triple therapy is yet to be established 
for efficiency and safety. Only one of such study is 
available thus we also suggest that this triple regimen 
in treatment of uncontrolled asthma should also be 
studied in future with larger population size.18  
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